The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Kidney Disease (CKD) Market Research Report 2025
Synopsis
The global Chronic Kidney Disease (CKD) market was valued at US$ 88540 million in 2023 and is anticipated to reach US$ 111810 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition characterized by persistent airflow limitation that makes it difficult to breathe. COPD encompasses a group of diseases, with the most common being emphysema and chronic bronchitis.
Emphysema involves the destruction of the air sacs in the lungs, while chronic bronchitis is marked by inflammation and narrowing of the airways. Symptoms include shortness of breath, chronic cough, excessive mucus production, wheezing, and tightness in the chest. COPD is often caused by long-term exposure to irritants, such as cigarette smoke, air pollution, and occupational dust or chemicals.
The condition is progressive and can significantly impact an individual's quality of life. In advanced stages, COPD can result in severe respiratory complications and exacerbations, potentially leading to hospitalizations.
Treatment for COPD typically involves a combination of medication, pulmonary rehabilitation, oxygen therapy, and in severe cases, surgical intervention such as lung volume reduction surgery or lung transplantation. Quitting smoking, avoiding lung irritants, and getting vaccinations to prevent respiratory infections are also essential components of COPD management.
COPD is a major public health concern globally, as it can cause significant morbidity and mortality. Early diagnosis, proper management, and lifestyle modifications are critical for maintaining the respiratory function and improving the well-being of individuals living with COPD.
This report aims to provide a comprehensive presentation of the global market for Chronic Kidney Disease (CKD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Kidney Disease (CKD).
Report Scope
The Chronic Kidney Disease (CKD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Kidney Disease (CKD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Kidney Disease (CKD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Allergan
Amgen
AstraZeneca
Roche
FibroGen
GlaxoSmithKline
Johnson & Johnson
Keryx
Kissei
Pfizer
Sanofi
Teva
Segment by Type
ACE Inhibitors
Calcium Channel Blockers
Beta Blockers
Others
Segment by Application
Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Kidney Disease (CKD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Chronic Kidney Disease (CKD) market was valued at US$ 88540 million in 2023 and is anticipated to reach US$ 111810 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition characterized by persistent airflow limitation that makes it difficult to breathe. COPD encompasses a group of diseases, with the most common being emphysema and chronic bronchitis.
Emphysema involves the destruction of the air sacs in the lungs, while chronic bronchitis is marked by inflammation and narrowing of the airways. Symptoms include shortness of breath, chronic cough, excessive mucus production, wheezing, and tightness in the chest. COPD is often caused by long-term exposure to irritants, such as cigarette smoke, air pollution, and occupational dust or chemicals.
The condition is progressive and can significantly impact an individual's quality of life. In advanced stages, COPD can result in severe respiratory complications and exacerbations, potentially leading to hospitalizations.
Treatment for COPD typically involves a combination of medication, pulmonary rehabilitation, oxygen therapy, and in severe cases, surgical intervention such as lung volume reduction surgery or lung transplantation. Quitting smoking, avoiding lung irritants, and getting vaccinations to prevent respiratory infections are also essential components of COPD management.
COPD is a major public health concern globally, as it can cause significant morbidity and mortality. Early diagnosis, proper management, and lifestyle modifications are critical for maintaining the respiratory function and improving the well-being of individuals living with COPD.
This report aims to provide a comprehensive presentation of the global market for Chronic Kidney Disease (CKD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Kidney Disease (CKD).
Report Scope
The Chronic Kidney Disease (CKD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Kidney Disease (CKD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Kidney Disease (CKD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Allergan
Amgen
AstraZeneca
Roche
FibroGen
GlaxoSmithKline
Johnson & Johnson
Keryx
Kissei
Pfizer
Sanofi
Teva
Segment by Type
ACE Inhibitors
Calcium Channel Blockers
Beta Blockers
Others
Segment by Application
Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Kidney Disease (CKD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Kidney Disease (CKD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ACE Inhibitors
1.2.3 Calcium Channel Blockers
1.2.4 Beta Blockers
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chronic Kidney Disease (CKD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Kidney Disease (CKD) Market Perspective (2019-2030)
2.2 Chronic Kidney Disease (CKD) Growth Trends by Region
2.2.1 Global Chronic Kidney Disease (CKD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Kidney Disease (CKD) Historic Market Size by Region (2019-2024)
2.2.3 Chronic Kidney Disease (CKD) Forecasted Market Size by Region (2025-2030)
2.3 Chronic Kidney Disease (CKD) Market Dynamics
2.3.1 Chronic Kidney Disease (CKD) Industry Trends
2.3.2 Chronic Kidney Disease (CKD) Market Drivers
2.3.3 Chronic Kidney Disease (CKD) Market Challenges
2.3.4 Chronic Kidney Disease (CKD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Kidney Disease (CKD) Players by Revenue
3.1.1 Global Top Chronic Kidney Disease (CKD) Players by Revenue (2019-2024)
3.1.2 Global Chronic Kidney Disease (CKD) Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Kidney Disease (CKD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Kidney Disease (CKD) Revenue
3.4 Global Chronic Kidney Disease (CKD) Market Concentration Ratio
3.4.1 Global Chronic Kidney Disease (CKD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Kidney Disease (CKD) Revenue in 2023
3.5 Chronic Kidney Disease (CKD) Key Players Head office and Area Served
3.6 Key Players Chronic Kidney Disease (CKD) Product Solution and Service
3.7 Date of Enter into Chronic Kidney Disease (CKD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Kidney Disease (CKD) Breakdown Data by Type
4.1 Global Chronic Kidney Disease (CKD) Historic Market Size by Type (2019-2024)
4.2 Global Chronic Kidney Disease (CKD) Forecasted Market Size by Type (2025-2030)
5 Chronic Kidney Disease (CKD) Breakdown Data by Application
5.1 Global Chronic Kidney Disease (CKD) Historic Market Size by Application (2019-2024)
5.2 Global Chronic Kidney Disease (CKD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Kidney Disease (CKD) Market Size (2019-2030)
6.2 North America Chronic Kidney Disease (CKD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Kidney Disease (CKD) Market Size by Country (2019-2024)
6.4 North America Chronic Kidney Disease (CKD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Kidney Disease (CKD) Market Size (2019-2030)
7.2 Europe Chronic Kidney Disease (CKD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Kidney Disease (CKD) Market Size by Country (2019-2024)
7.4 Europe Chronic Kidney Disease (CKD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Kidney Disease (CKD) Market Size (2019-2030)
8.2 Asia-Pacific Chronic Kidney Disease (CKD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Kidney Disease (CKD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Kidney Disease (CKD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Kidney Disease (CKD) Market Size (2019-2030)
9.2 Latin America Chronic Kidney Disease (CKD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Kidney Disease (CKD) Market Size by Country (2019-2024)
9.4 Latin America Chronic Kidney Disease (CKD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Kidney Disease (CKD) Market Size (2019-2030)
10.2 Middle East & Africa Chronic Kidney Disease (CKD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Kidney Disease (CKD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Kidney Disease (CKD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Chronic Kidney Disease (CKD) Introduction
11.1.4 AbbVie Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Chronic Kidney Disease (CKD) Introduction
11.2.4 Allergan Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.2.5 Allergan Recent Development
11.3 Amgen
11.3.1 Amgen Company Detail
11.3.2 Amgen Business Overview
11.3.3 Amgen Chronic Kidney Disease (CKD) Introduction
11.3.4 Amgen Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.3.5 Amgen Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Chronic Kidney Disease (CKD) Introduction
11.4.4 AstraZeneca Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.4.5 AstraZeneca Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Chronic Kidney Disease (CKD) Introduction
11.5.4 Roche Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.5.5 Roche Recent Development
11.6 FibroGen
11.6.1 FibroGen Company Detail
11.6.2 FibroGen Business Overview
11.6.3 FibroGen Chronic Kidney Disease (CKD) Introduction
11.6.4 FibroGen Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.6.5 FibroGen Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Detail
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Chronic Kidney Disease (CKD) Introduction
11.7.4 GlaxoSmithKline Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.7.5 GlaxoSmithKline Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Chronic Kidney Disease (CKD) Introduction
11.8.4 Johnson & Johnson Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.8.5 Johnson & Johnson Recent Development
11.9 Keryx
11.9.1 Keryx Company Detail
11.9.2 Keryx Business Overview
11.9.3 Keryx Chronic Kidney Disease (CKD) Introduction
11.9.4 Keryx Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.9.5 Keryx Recent Development
11.10 Kissei
11.10.1 Kissei Company Detail
11.10.2 Kissei Business Overview
11.10.3 Kissei Chronic Kidney Disease (CKD) Introduction
11.10.4 Kissei Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.10.5 Kissei Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Detail
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Chronic Kidney Disease (CKD) Introduction
11.11.4 Pfizer Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.11.5 Pfizer Recent Development
11.12 Sanofi
11.12.1 Sanofi Company Detail
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Chronic Kidney Disease (CKD) Introduction
11.12.4 Sanofi Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.12.5 Sanofi Recent Development
11.13 Teva
11.13.1 Teva Company Detail
11.13.2 Teva Business Overview
11.13.3 Teva Chronic Kidney Disease (CKD) Introduction
11.13.4 Teva Revenue in Chronic Kidney Disease (CKD) Business (2019-2024)
11.13.5 Teva Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
